Subcontracting Opportunities
Subcontracting allows small and disadvantaged businesses to substantially impact the federal procurement preference programs. Due to legislative mandates, federal prime contractors award billions of subcontracting dollars annually to small businesses — Small Business Subcontracting Plan requirements set forth in their contracts include requirements to track participation by veteran-owned, service-disabled veteran-owned, HUBZone, disadvantaged, and women-owned businesses.
USASpending.gov provides information on organizations who have a prime contractor relationship with the NCI. The current Frederick National Laboratory for Cancer Research (FNLCR) prime contractor has significant subcontracting opportunities — see FNLCR Acquisitions for further information.
NCI also maintains a list of its active Indefinite Delivery/Indefinite Quantity (ID/IQ) Prime Contractors. NCI encourages businesses to network and establish teaming arrangements to support these contracting vehicles, which are used to place a variety of orders for supplies and services through processes that do not involve public posting after the base ID/IQ contract(s) have been awarded.
| Contract Name(s) | Contract Specialist | Title & Brief Description From Article B.1. | Base Period of Performance (Start-End Dates) |
|---|---|---|---|
| North American Association of Central Cancer Registries (NAACCR) | Kate Muir | The objective of this contract is provide support to the North American Association of Central Cancer Registries (NMCCR) in order to make the National Cancer lnstitute's (NCI) cancer surveillance program more responsive to the needs of the division, institute, and nation, and more integrated with other partners within the national cancer surveillance enterprise.This contract focuses on three specific areas: (1) Strengthening the national capacity for collecting, analyzing, and using comparable cancer registry data for cancer surveillance and research. (2) Developing and improving methods for assessing the quality and comparability of cancer registry data. This includes, but is not limited to timeliness, completeness, and accuracy. (3) Improving the efficiency and quality of registry operationsthrough promoting established standards, disseminating technical information, and facilitating collaboration among Federal, state, provincial and local registry professionals. |
7/1/2014 - 6/30/2021 |
| Becton Dickinson | Miguel Diaz | Consumable reagents and Maintenenace for Government Owned Becton Dickinson Instruments | 6/28/2018 - 6/27/2021 |
| IITRI | Randall Tiqui | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 7/1/2014 - 6/30/2021 |
| SRI International | Lexi Hudak | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 7/1/2014 - 6/30/2021 |
| Southern Research | Lexi Hudak | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 7/1/2014 - 6/30/2021 |
| University of Pittsburgh | Lexi Hudak | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 7/1/2014 - 6/30/2021 |
| IITRI | Lexi Hudak | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 7/1/2014 - 6/30/2021 |
| Mayo Clinic | Lexi Hudak | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 7/1/2014 - 6/30/2021 |
| Battelle | Randall Tiqui | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 7/1/2016 - 6/30/2021 |
| SRI | Randall Tiqui | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 7/1/2016 - 6/30/2021 |
| Southern Research Institute | Randall Tiqui | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 7/1/2016 - 6/30/2021 |
| UIC | Randall Tiqui | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 7/1/2016 - 6/30/2021 |
| Ganges, Mary Bruce Biological Research Consultant | Jolomi Omatete | Tissue Culture technician support p to 9000 hours with a minimum of 1400 hours | 8/20/2016 - 8/19/2021 |
| Vignet | Apisit Viriya | This contract shall provide technical services to the Applied Research Program (ARP), in the Division of Cancer Control and Population Sciences (DCCPS) within the National Cancer Institute (NCI). ARP has needs for developmental and technical services in a broad range of content areas, including cancer-associated health behaviors, health services, and outcomes from cancer treatment. Within each of these content areas, common needs are for study management, questionnaire development, and database development and management | 9/12/2014 - 9/11/2021 |
| CDM Group | Apisit Viriya | Technical Services for the NCI Applied Research Program - This contract provides a broad range of developmental and technical services related to cancer-associated health behaviors, health services and outcomes for cancer treatment. The services include study management, questionnaire development, and database development and management. | 9/12/2014 - 9/11/2021 |
| Gunnison | Apisit Viriya | Technical Services for the NCI Applied Research Program - This contract provides a broad range of developmental and technical services related to cancer-associated health behaviors, health services and outcomes for cancer treatment. The services include study management, questionnaire development, and database development and management. | 9/12/2014 - 9/11/2021 |
| Vsolvit | Apisit Viriya | Technical Services for the NCI Applied Research Program - This contract provides a broad range of developmental and technical services related to cancer-associated health behaviors, health services and outcomes for cancer treatment. The services include study management, questionnaire development, and database development and management. | 9/12/2014 - 9/11/2021 |
| Vanderbilt University Medical Center | Miguel Diaz | Laboratory Testing Services for Circulating Inflammation Markers and Prospective Risk of Gastric Cancer Related to the H Pylor | 9/14/2016 - 9/13/2021 |
| D's Ventures LLC, dba LOGMET | Megan Kisamore | Procurement of Gardasil-9 Vaccines in support of NCI/CCR | 9/18/2018 - 9/18/2021 |
| Invitae Corporation | David Romley | Lab Testing/Dicer I Genetic Testing | 9/19/2016 - 9/21/2021 |
| Olink Proteomics AB | Renee Jones-Chuang | Analysis Services to Evaluate the Circulating Biomarkers in Cancer | 12/18/2020 - 12/17/2021 |
| Planon Corporation | Renee Jones-Chuang | Procurement of Computer Aided Facility Management (CAFM) Software System Support, | 9/14/2020 - 12/31/2021 |
| American Type Culture Collection | Michele Brown | The Contractor shall provide Molecular Epidemiology Assay Support (MEAS) to the Division of Cancer Epidemiology and Genectics. | 5/6/2017 - 3/5/2022 |
| Metabolon, Inc. | Michele Brown | The Contractor shall provide metabolomic profiling services for DCEG studies using liquid chromatography and gas chromatography mass spectrometry (LC-MS). | 6/14/2017 - 6/13/2022 |
| MRIGlobal | Junli Collins | Analysis of bulk drug samples and their pharmaceutical formulations | 8/1/2017 - 7/31/2022 |
| RTI International | Junli Collins | Analysis of bulk drug samples and their pharmaceutical formulations | 8/1/2017 - 7/31/2022 |
| SRI International | Junli Collins | Analysis of bulk drug samples and their pharmaceutical formulations | 8/1/2017 - 7/31/2022 |
| Nationwide Children's Hospital | Wilkison, Paula | Biospcimen Core Resource (BCR) | 8/25/2017 - 8/24/2022 |
| Bizzell Group | Park, Linda | Tobacco Control Research Scientific and Technical Services Support | 9/1/2017 - 8/31/2022 |
| Bayer Healthcare LLC | Jolomi Omatete | BPX30 Disposable Endorectal Coils for 3.OT MRI Scanner | 9/10/2017 - 9/17/2022 |
| Genepria Consulting Inc. | Jolomi Omatete | Statistical and Programming Appplications | 9/12/2017 - 9/11/2022 |
| Alchem | Christine Biser | Synthesis of Non-GMP Small Molecules | 9/18/2017 - 9/17/2022 |
| ASE Direct Inc. | Adam Hernandez | Erlotinib Tablets | 1/24/2020 - 1/23/2023 |
| Fundacion INCIENSA | Michele Brown | Evaluation of Single Dose Protection Afforded by the Prophylactic HPV vaccines | 8/1/2017 - 7/31/2023 |
| Medidata Solutions | Pooja Rathore | Rave Hosting, Maintenance, and Professional Services, and License, Hosting, Maintenance, and Professional Services for Rave integrated anicillary services. | 9/1/2018 - 8/31/2023 |
| Synergy | Randall Tiqui | NCI Center for Global Health, Logistics, Data Analysis and Technical Support | 9/17/2018 - 9/16/2023 |
| IIT Research Institute | Kelly Fowler | PREVENT Preclinical Drug Development Program (Efficacy Pool) | 1/25/2019 - 1/24/2024 |
| IIT Research Institute | Kelly Fowler | PREVENT Preclinical Drug Development Program (Efficacy Pool) | 1/25/2019 - 1/24/2024 |
| SRI International | Kelly Fowler | PREVENT Efficacy studies | 1/25/2019 - 1/24/2024 |
| SRI International | Kelly Fowler | PREVENT Preclinical Drug Development Program (Efficacy Pool) | 1/25/2019 - 1/24/2024 |
| University of Alabama at Birmingham | Kelly Fowler | PREVENT Efficacy studies | 1/25/2019 - 1/24/2024 |
| University of Oklahoma Health Sciences Center | Kelly Fowler | PREVENT Efficacy studies | 1/25/2019 - 1/24/2024 |
| Illinois Univ, TRL | Christy Hunter | PREVENT Efficacy studies | 1/25/2019 - 1/24/2024 |
| University of Texas, MD Anderson | Christy Hunter | PREVENT Efficacy studies | 1/25/2019 - 1/24/2024 |
| The Research Institute of Fox Chase Cancer Center | Christy Hunter | PREVENT Efficacy studies | 1/25/2019 - 1/24/2024 |
| Illinois Univ, TRL | Christy Hunter | PREVENT Preclinical Drug Development Program (Toxicology Pool) | 1/25/2019 - 1/24/2024 |
| Southern Research Institute | Christy Hunter | PREVENT Preclinical Drug Development Program (Toxicology Pool) | 1/25/2019 - 1/24/2024 |
| Advanced Bioscience Laboratories | Megan Osele | PREVENT Preclinical Drug Development Program: CGMP Production of Vaccines and Biologicals for Cancer Prevention | 8/14/2019 - 1/24/2024 |
| International AIDS Vaccine Initiative | Megan Osele | PREVENT Preclinical Drug Development Program: CGMP Production of Vaccines and Biologicals for Cancer Prevention | 8/14/2019 - 1/24/2024 |
| Kindred Biosciences | Megan Osele | PREVENT Preclinical Drug Development Program: CGMP Production of Vaccines and Biologicals for Cancer Prevention | 8/14/2019 - 1/24/2024 |
| Leidos Biomedical Research | Scott Keasey | The Contractor shall, in accordance with the provisions of this contract, support the missions and programs assigned under contract with the National Cancer Institute and manage and operate the National Cancer Institute’s Federally Funded Research and Development Center (FFRDC)/Frederick National Laboratory for Cancer Research (FNLCR). The purpose of the FFRDC is to provide a unique biomedical research and development resource for the development of new technologies and the translation of basic science discoveries into novel agents for the prevention, diagnosis, and treatment of cancer, Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS), and other diseases in support of the NCI, NIAID, other NIH ICs and other government agencies. The FFRDC serves as a flexible, quick-response mechanism to accomplish the most urgent national/global health initiatives for the NCI/NIH and other government agencies. | 6/26/2019 - 6/25/2024 |
| Carl Zeiss | Miguel Diaz | Maintenance Service Support for Zeiss Confocal and Epifluorescence Microscopes at the NCI CCR Microscopy Core Facilities. | 8/1/2019 - 7/31/2024 |
| The University of North Carolina at Chapel Hill | Lexi Hudak | NCI's Genomics Characterization Center | 8/31/2019 - 8/30/2024 |
| University of California | Lexi Hudak | NCI's Genomics Characterization Center | 8/31/2019 - 8/30/2024 |
| Washington University in St. Louis | Lexi Hudak | NCI's Genomics Characterization Center | 8/31/2019 - 8/30/2024 |
| The Broad Institute, Inc | Lexi Hudak | NCI's Genomic Characterization Center IDIQ Contract | 8/31/2019 - 8/30/2024 |
| Genewiz, LLC | Lexi Hudak | NCI's Genomic Characterization Center IDIQ Contract | 8/31/2019 - 8/30/2024 |
| New York Genome Center | Lexi Hudak | NCI's Genomic Characterization Center IDIQ Contract | 8/31/2019 - 8/30/2024 |
| University of North Carolina at Chapel Hills | Lexi Hudak | NCI's Genomic Characterization Center IDIQ Contract | 8/31/2019 - 8/30/2024 |
| University of Southern California | Lexi Hudak | NCI's Genomic Characterization Center IDIQ Contract | 8/31/2019 - 8/30/2024 |
| Washington University | Lexi Hudak | NCI's Genomic Characterization Center IDIQ Contract | 8/31/2019 - 8/30/2024 |
| Roche Diagnostics Corporation | Jolomi Omatete | BenchMark Ultra Reagents and Consumables | 9/22/2019 - 9/21/2024 |
| PR Strategist | Jolomi Omatete | NCI/OWPD workforce training and facilitation Services | 2/19/2020 - 2/18/2025 |
| PBG Consulting LLC | Junli Collins | NCI CSSI Technical, Programmatic and Other Support Services | 7/15/2020 - 7/14/2025 |
| Booz Allen Hamilton | Tom Conroy | Biomedical Information Management and Analytic Support Services | 9/16/2020 - 9/15/2025 |
| Deloitte | Tom Conroy | Biomedical Information Management and Analytic Support Services | 9/16/2020 - 9/15/2025 |
| Information Management Services, Inc. | Tom Conroy | Biomedical Information Management and Analytic Support Services | 9/16/2020 - 9/15/2025 |
| Research Triangle Institute | Tom Conroy | Biomedical Information Management and Analytic Support Services | 9/16/2020 - 9/15/2025 |
| Westat | Tom Conroy | Biomedical Information Management and Analytic Support Services | 9/16/2020 - 9/15/2025 |
| Connecticut Department of Public Health | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Emory University | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Fred Hutchinson Cancer Research Center | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Health Research, Inc. | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Idaho Hospital Association | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Louisiana State University | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Massachusetts Department of Public Health | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Public Health Institute | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Cancer Prevention Institute of California (CPIC) | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| UCSF | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| University of Southern California | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| University of Hawaii | Randy Cook | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| University of Iowa | Randy Cook | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| University of Kentucky (Research Foundation) | Randy Cook | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| University of New Mexico | Randy Cook | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| University of Utah | Randy Cook | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Wisconsin Department of Health Services | Randy Cook | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Rutgers | Mark Brady | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 3/3/2021 - 4/30/2028 |
| Illinois | Randy Cook | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 3/3/2021 - 4/30/2028 |
| Arkansas Department of Health | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| Colorado Department of Public Health and Enviornment | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| The Curators of the University of Missouri | Randy Cook | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| Michigan Department of Health and Human Services | Mark Brady | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| Oregon Health & Science University | Mark Brady | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| Tennessee Department of Health | Randy Cook | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| Texas Department of State Health Services | Brittany Gibau | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| Trustees of Dartmouth College | Mark Brady | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| Wayne State University | Mark Brady | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| California Department of Public Health | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 6/1/2021 - 4/30/2028 |
| Kaiser Foundation Hospitals | Nikki Arena | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 6/4/2018 - 6/3/2028 |
| The University of Chicago | Nikki Arena | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 6/4/2018 - 6/3/2028 |
| Henry Ford Health System | Bryan Dankanich | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 6/4/2018 - 6/3/2028 |
| Sanford Research | Bryan Dankanich | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 6/4/2018 - 6/3/2028 |